BiotechTube
CDx Diagnostics

CDx Diagnostics

Phoenix, United States· Est.
cdxdiagnostics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CDx Diagnostics is a commercial-stage diagnostics company specializing in AI-powered early cancer detection. Its flagship product, WATS 3D, is an adjunctive test for esophageal precancer that combines enhanced tissue sampling with a neural network for analysis and 3D imaging, recently receiving FDA Breakthrough Device Designation. The company targets the significant market for Barrett's esophagus surveillance, aiming to improve patient outcomes and reduce healthcare costs by catching dysplasia earlier than standard biopsies. It operates as a private company, generating revenue through its diagnostic testing services.

OncologyGastroenterology

Technology Platform

Integrated diagnostic platform combining proprietary wide-area transepithelial sampling devices, advanced 3D digital imaging, and an AI-powered neural network for the analysis of tissue to detect precancerous dysplasia.

Opportunities

Significant market in Barrett's esophagus surveillance, with potential to improve standard of care and reduce costly late-stage cancer treatment.
The FDA Breakthrough Device Designation provides a accelerated regulatory pathway and validation.
The core AI-platform is adaptable to other tissue types and cancers, enabling pipeline expansion.

Risk Factors

Commercial success depends on securing consistent insurance reimbursement and changing physician practice habits.
Faces competition from emerging AI pathology platforms and potential technological disruption.
Execution risk in scaling a specialized diagnostic service while maintaining quality and turnaround time.

Competitive Landscape

Competes against the entrenched standard of care (forceps biopsies) and other adjunctive techniques like chromoendoscopy. Faces emerging competition from other AI-based digital pathology software companies analyzing standard biopsy slides. Potential future competition from other wide-area sampling technologies or comprehensive genomic profiling tests.

More companies in Diagnostics & Precision Medicine →More companies in United States →